Oral Prophylaxis with Berotralstat (BCX7353) Reduces Use of Standard of Care (SOC) On-demand Medication in Patients with Hereditary Angioedema (HAE): APeX-2 Study Results

被引：0

作者：

Bernstein, Jonathan ^{[1
]}

Zuraw, Bruce ^{[2
]}

Aygoren-Pursun, Emel ^{[3
]}

Li, Huamin ^{[4
]}

Busse, Paula ^{[5
]}

Johnston, Douglas ^{[6
]}

Maurer, Marcus ^{[7
]}

Lumry, William ^{[6
]}

Riedl, Marc ^{[2
]}

Jacobs, Joshua ^{[8
]}

Sitz, Karl ^{[9
]}

Gagnon, Remi ^{[10
]}

Clemons, Desiree ^{[11
]}

Dobo, Sylvia ^{[11
]}

Nagy, Eniko ^{[11
]}

Murray, Sharon ^{[11
]}

Collis, Philip ^{[11
]}

Sheridan, William ^{[11
]}

Banerji, Aleena ^{[12
]}

机构：

[1] Univ Cincinnati, Cincinnati, OH 45221 USA

[2] Univ Calif San Diego, La Jolla, CA 92093 USA

[3] Univ Klinikum Frankfurt, Frankfurt, Germany

[4] Inst Asthma & Allergy, Chevy Chase, MD USA

[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA

[6] Asthma & Allergy Specialists, Blue Bell, PA USA

[7] Charite Univ Med Berlin, Berlin, Germany

[8] Allergy & Asthma Clin Res, Oklahoma City, OK USA

[9] Little Rock Allergy & Asthma Clin Res Ctr, Little Rock, AR USA

[10] Clin Specialisee Allergie Capitale, Quebec City, PQ, Canada

[11] BioCryst Pharmaceut Inc, Durham, NC USA

[12] Massachusetts Gen Hosp, Boston, MA 02114 USA

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2020年 / 145卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

328

引用

页码：AB106 / AB106

页数：1

共 18 条

[1] ORAL PROPHYLAXIS WITH BCX7353 REDUCES HAE ATTACK RATES AND IS WELL-TOLERATED: APEX-2 STUDY RESULTS
Zuraw, B.
Lumry, W.
Banerji, A.
Aygoren-Pursun, E.
Bernstein, J.
Johnston, D.
Christiansen, S.
Riedl, M.
Cicardi, M.
Maurer, M.
Cornpropst, M.
Dobo, S.
Iocca, H.
Nagy, E.
Murray, S.
Collis, P.
Sheridan, W.
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S27 - S27
[2] Long-term safety and tolerability of Berotralstat (BCX7353) for Hereditary Angioedema (HAE) prophylaxis: APeX-S study results
Farkas, H.
Wu, A. Y.
Kiani, S.
Reshef, A.
Stobiecki, M.
Kinaciyan, T.
Maurer, M.
Aygoren-Pursun, E.
Dix, D.
Dobo, S.
Iocca, H.
Murray, S.
Sheridan, W. P.
Peter, J.
[J]. ALLERGY, 2020, 75 : 58 - 59
[3] Relative Reductions in Attack Rate With Prophylactic Berotralstat (BCX7353) in Subjects with Hereditary Angioedema (HAE): Responder Analysis from the APeX-2 Study
Lumry, William
Maurer, Marcus
Zuraw, Bruce
Banerji, Aleena
Riedl, Marc
Johnston, Douglas
Aygoren-Pursun, Emel
Jacobs, Joshua
Gower, Richard
Wedner, H. James
Sitz, Karl
Magerl, Markus
Cornpropst, Melanie
Elder, Jennifer
Iocca, Heather
Nagy, Eniko
Murray, Sharon
Collis, Philip
Sheridan, William
Christiansen, Sandra
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB105 - AB105
[4] Long-term effectiveness of berotralstat (BCX7353) for the prophylaxis of hereditary angioedema (HAE) attacks: Results from the APeX-S study
Reshef, A.
Maurer, M.
Kiani, S.
Wu, A. Y.
Stobiecki, M.
Kinaciyan, T.
Peter, J.
Aygoren-Pursun, E.
Cornpropst, M.
Nagy, E.
Murray, S.
Collis, P.
Farkas, H.
[J]. ALLERGY, 2020, 75 : 210 - 211
[5] Long-term safety and effectiveness of berotralstat (BCX7353) for the prophylaxis of hereditary angioedema (HAE) attacks: Results from the APeX-S study
Kiani, Sorena
Wu, Adrian
Peter, Jonathan
Reshef, Avner
Maurer, Marcus
Stobiecki, Marcin
Kinaciyan, Tamar
Aygoeren-Puersuen, Emel
Best, Jessica
Cornpropst, Melanie
Sheridan, William P.
Farkas, Henriette
[J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (01): : 172 - 173
[6] Patterns of Treatment and Retreatment of Acute Attacks of Hereditary Angioedema (HAE) with Standard of Care (SOC) On-Demand Medication: Results from the APeX-2 Study
Aygoren-Pursun, Emel
Johnston, Douglas
Lumry, William
Li, Huamin
Banerji, Aleena
Zuraw, Bruce
Christiansen, Sandra
Kinaciyan, Tamar
Hanzlikova, Jana
Gower, Richard
Gagnon, Remi
Cicardi, Marco
Cornpropst, Melanie
Dobo, Sylvia
Hutchinson, Kathryn
Iocca, Heather
Nagy, Eniko
Murray, Sharon
Sheridan, William
Bernstein, Jonathan
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB107 - AB107
[7] Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)
Wedner, H. James
Aygoeren-Puersuen, Emel
Bernstein, Jonathan
Craig, Timothy
Gower, Richard
Jacobs, Joshua S.
Johnston, Douglas T.
Lumry, William R.
Zuraw, Bruce L.
Best, Jessica M.
Iocca, Heather A.
Murray, Sharon C.
Desai, Bhavisha
Nagy, Eniko
Sheridan, William P.
Kiani-Alikhan, Sorena
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (06): : 2305 - +
[8] Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study
Aygoren-Pursun, E.
Johnston, D.
Banerji, A.
Bernstein, J. A.
Yang, W. H.
Fritz, S.
Zuraw, B.
Mcneil, D.
Cornpropst, M.
Murray, S.
Nagy, E.
Collis, P.
Craig, T.
[J]. ALLERGY, 2020, 75 : 457 - 458
[9] BEROTRALSTAT REDUCES ATTACKS IN PATIENTS WITH HEREDITARY ANGIOEDEMA (HAE): APEX-2 TRIAL 48 WEEK RESULTS
Wedner, H.
Zuraw, B.
Anderson, J.
Craig, T.
Kiani, S.
Iocca, H.
Best, J.
Murray, S.
Maurer, M.
[J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2020, 125 (05) : S14 - S14
[10] Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On-Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH-1 Trial
Longhurst, Hilary
Moldovan, Dumitru
Bygum, Anette
Cicardi, Marco
Huissoon, Aarnoud
Aygoren-Pursun, Emel
Grivcheva-Panovska, Vesna
Hagin, David
Steiner, Urs
Stobiecki, Marcin
Aberer, Werner
Bethune, Claire
Faust, Saul N.
Kiani, Sorena
Launay, David
Maurer, Marcus
Rae, William
Reshef, Avner
Cornpropst, Melanie T.
Dobo, Sylvia M.
VanDyke, Sharon
Murray, Sharon
Collis, Phillip J.
Sheridan, William P.
Farkas, Henriette
[J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB37 - AB37

← 1 2 →